A Aralex Aachen research explorer

August 03, 2015 article Open access

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

Nephrology Dialysis Transplantation

DOI: 10.1093/ndt/gfv302 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 3 stored of 286

Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)
2021 Nephrology Dialysis Transplantation article Medicine Erythropoietin and Anemia Treatment Open access

121

citations
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan
2020 Journal of the American Society of Nephrology article Medicine Erythropoietin and Anemia Treatment Open access

208

citations
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis
2020 The Nephron journals/Nephron journals article Medicine Erythropoietin and Anemia Treatment Open access

63

citations

3 results

References 0